Abiopharma

Definium Therapeutics Common Shares to Trade under New Nasdaq Ticker Symbol “DFTX” Effective January 15, 2026

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

(85% Positive) Onconova Therapeutics Inc. (was merged with Trawsfynydd Therapeutics, Inc. on 02/04/2024) (ONTX) Files Form 8-K

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

Energous Reports Preliminary Financial Results for Fiscal Year 2025, Marking a Transformational Year of Growth and Platform Expansion

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Sono-Tek Reports Fiscal Third Quarter and Nine-Month Fiscal 2026 Financial Results

New Form 425 - WATERS CORP /DE/ Filed: 2026-01-13 AccNo: 0001193125-26-011092 Size: 75 KB

SciSparc Notification (SPRC)

SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity

(85% Positive) Cardinal Health Inc (CAH) Reports Q1 2026 Financial Results